Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure

Thrombosis Research

Volumn 109, Issue 5-6, 2003, Pages 259-263

  Brueckmann, Martina ^a   Wizenmann, Jan ^a   Hoffmann, Ursula ^a   Seeger, Markus ^b   Bewig, Burkhard ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Coagulopathy; Inflammation; Intensive care medicine; Multiple organ failure; Recombinant human activated protein C; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DOPAMINE; DROTRECOGIN; ERYTHROMYCIN; HYPERTENSIVE FACTOR; NORADRENALIN; PIPERACILLIN; RECOMBINANT PROTEIN; TAZOBACTAM; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; FEMALE; GENERAL CONDITION IMPROVEMENT; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPOTENSION; INFLAMMATION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LAPAROSCOPY; MULTIPLE ORGAN FAILURE; PERIRENAL ABSCESS; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPTIC SHOCK; URINARY TRACT INFECTION;

EID: 0038683400     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00243-3     Document Type: Article

References (18)

1. Esmon C.T., Taylor F.B. Jr., Snow T.R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb. Haemost. 66:1991;160-165.
2. Van Deventer S.J., Buller H.R., ten Cate J.W., Aarden L.A., Hack C.E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 76:1990;2520-2526.
3. Esmon C.T. The protein C anticoagulant pathway. Arterioscler. Thromb. 12:1992;135-145.
4. Van Hinsbergh V.W., Bertina R.M., van Wijngaarden A., van Tilburg N.H., Emeis J.J., Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 65:1995;444-451.
5. Bajzar L., Nesheim M.E., Tracy P.B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 88:1996;2093-2100.
6. Yan S.B., Razzano P., Chao Y.B., Walls J.D., Berg D.T., McClure D.B.et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (NY). 8:1990;655-661.
7. Yan S.B., Grinnell B.W. Recombinant human protein C, protein S, and thrombomodulin as antithrombotics. Perspect. Drug Discovery Des. 1:1993;503-520.
8. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H.et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 87:1996;642-647.
9. Grinnell B.W., Hermann R.B., Yan S.B. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosulated oligosaccharide. Glycobiology. 4:1994;221-225.
10. Grey S.T., Tsuchida A., Hau H., Orthner C.L., Salem H.H., Hancock W.W. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J. Immunol. 153:1994;3664-3672.
11. Fisher C.J., LaRosa S.P., Helterbrand J.D., Bernard G.R. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities, morbidity and 28 day mortality in patients with severe sepsis. J. Antimicrob. Chemother. 44(Suppl. A):1999;10.
12. Bernard G.R.et al. Efficacy and safety of recombinant activated protein C for severe sepsis. N. Engl. J. Med. 344:2001;699-709.
13. Vincent J.L., Moreno R., Takala J., Willats S., De Mendonca A., Bruining H.et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22:1996;707-710.
14. Monneret G., Labaune J.M., Isaac C., Bienvenu F., Putet G., Bienvenu J. Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr. 86:1997;209-212.
15. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 103:1993;565-575.
16. Friedland J.S., Porter J.C., Daryanani S., Bland J.M., Screaton N.J., Vesely M.J.et al. Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit. Care Med. 24:1996;1775-1781.
17. Schröder J., Staubach K.H., Zabel P., Stüber F., Kremer B. Procalcitonin as a marker of severity in septic shock. Langenbeck's Arch. Surg. 384:1999;33-38.
18. Smith-Erichsen N., Aasen A.O., Gallimore M.J., Amundsen E. Studies of components of the coagulation system in normal individuals and septic shock patients. Circ. Shock. 9:1982;491-497.